Table 4.
Nanotherapeutics approved for oncological therapy.
| Name | Particle Base | Anticancer Drug | Cancer Type | Approval |
|---|---|---|---|---|
| Liposome-based | ||||
| Doxil/Caelyx (Janssen) | PEGylated liposome | Doxorubicin | Ovarian, breast cancer, leukemia | FDA, 1995 |
| DaunoXome (Galen) | Non-PEGylated liposome | Daunorubicin | HIV-related Kaposi sarcoma | FDA, 1996 |
| DepoCyt (Pacira) | Non-PEGylated liposome | Cytarabine | AML, non-Hodgkin lymphoma | FDA,1999 |
| Myocet (Teva UK) | Non-PEGylated liposome | Doxorubicin | Metastatic breast cancer | EMA, 2000 |
| Marqibo (Spectrum) | Non-PEGylated liposome | Vincristine | Ph-ALL, Non-Hodgkin’s lymphoma | FDA, 2012 |
| Onivyde (Merrimack) | PEGylated liposome | irinotecan | Breast, pancreatic, sarcomas, or brain | FDA, 2015 |
| Polymer-based | ||||
| Oncaspar (Sigma Tau) | PEGylation | L-asparaginase | ALL | FDA,1994 |
| Abraxane (Celgene) | Albumin-bound polymer | Paclitaxel | Metastatic pancreatic cancer | FDA, 2005 |